Fielmann AG (FLMNY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Fielmann AG (FLMNY) with AI Score 48/100 (Weak). Fielmann AG is a German-based optical and hearing aid business operating across Europe. The company manufactures and sells visual and hearing aids through its extensive network of retail stores and online platforms. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Fielmann AG (FLMNY) Healthcare & Pipeline Overview
Fielmann AG is a leading European optical and hearing aid provider, distinguished by its vertically integrated business model, encompassing manufacturing, retail, and online sales. With a strong presence in Germany and expanding operations across Europe, Fielmann offers a wide range of eyewear and hearing solutions, catering to diverse customer needs.
Investment Thesis
Fielmann AG presents a notable research candidate based on its established market position, vertically integrated business model, and expansion strategy. The company's strong brand recognition and extensive retail network provide a solid foundation for growth. With a P/E ratio of 19.57 and a profit margin of 7.5%, Fielmann demonstrates financial stability. A dividend yield of 2.70% offers income potential for investors. Key catalysts include continued expansion in Southern and Eastern Europe, and increased online sales. Potential risks include increased competition and fluctuations in currency exchange rates. The company's beta of 0.65 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $4.17 billion, reflecting its significant presence in the European optical market.
- Gross margin of 80.2%, indicating efficient cost management and strong pricing power.
- Operates 693 stores across Europe as of December 31, 2021, providing extensive retail coverage.
- Dividend yield of 2.70%, offering a steady income stream for investors.
- Employs 20,221 people, showcasing its operational scale and market reach.
Competitors & Peers
Strengths
- Strong brand recognition in Europe
- Extensive retail network
- Vertically integrated business model
- High gross margin
Weaknesses
- Limited presence outside of Europe
- Dependence on retail sales
- Exposure to currency fluctuations
- Competition from online retailers
Catalysts
- Ongoing: Expansion into new European markets, driving revenue growth.
- Ongoing: Increased online sales through enhanced e-commerce platform.
- Upcoming: Potential partnerships with healthcare providers to offer integrated services.
- Ongoing: Product innovation and development of advanced lens technologies.
Risks
- Potential: Increased competition from existing players and new entrants.
- Potential: Fluctuations in currency exchange rates impacting profitability.
- Potential: Economic downturns affecting consumer spending on discretionary items.
- Ongoing: Regulatory changes in the healthcare industry.
- Potential: Supply chain disruptions affecting product availability.
Growth Opportunities
- Expansion in Southern and Eastern Europe: Fielmann has the opportunity to further expand its presence in Southern and Eastern European markets, where demand for affordable and high-quality optical and hearing solutions is growing. This expansion could involve opening new stores, acquiring existing businesses, or establishing partnerships with local retailers. This offers potential to capture a larger share of the European market, estimated to reach $45 billion by 2028.
- Increased Online Sales: Fielmann can leverage its online platform to drive sales growth and reach a wider customer base. By investing in e-commerce capabilities, digital marketing, and online customer service, the company can capitalize on the increasing trend of online shopping for eyewear and hearing aids. The global e-commerce market for eyewear is projected to reach $22 billion by 2027.
- Product Innovation: Fielmann can invest in research and development to introduce new and innovative products that cater to evolving customer needs and preferences. This could include developing advanced lens technologies, smart glasses, or personalized hearing solutions. The global market for smart glasses is expected to reach $15 billion by 2028.
- Partnerships with Healthcare Providers: Fielmann can forge strategic partnerships with healthcare providers, such as ophthalmologists and audiologists, to offer integrated eye and hearing care solutions. This could involve establishing co-located clinics, offering referral programs, or developing joint marketing campaigns. This can drive customer acquisition and enhance brand reputation.
- Focus on Sustainability: Fielmann can enhance its brand image and attract environmentally conscious customers by adopting sustainable business practices. This could include using eco-friendly materials, reducing waste, and promoting ethical sourcing. The global market for sustainable eyewear is growing, driven by increasing consumer awareness of environmental issues.
Opportunities
- Expansion into new geographic markets
- Growth in online sales
- Development of innovative products
- Partnerships with healthcare providers
Threats
- Increased competition
- Changing consumer preferences
- Economic downturns
- Regulatory changes
Competitive Advantages
- Strong brand recognition in the European market.
- Extensive retail network providing convenient access for customers.
- Vertically integrated business model enabling cost control and quality assurance.
- Long-standing relationships with suppliers and partners.
About FLMNY
Founded in 1972 and headquartered in Hamburg, Germany, Fielmann Aktiengesellschaft has grown to become a prominent player in the European optical and hearing aid market. The company operates through a network of 693 stores as of December 31, 2021, with a significant presence in Germany (610 stores), Switzerland (45), Austria (38), Italy (43), Poland (37), and Spain (87), along with smaller operations in Luxembourg, Slovenia, and other Eastern European countries. Fielmann manufactures and sells a comprehensive range of visual aids, including glasses, frames, lenses, sunglasses, contact lenses, and accessories. Additionally, the company offers hearing aids and related accessories. Fielmann's business model integrates manufacturing, retail distribution, and online sales channels. Fielmann Aktiengesellschaft is a subsidiary of Korva SE.
What They Do
- Manufactures and sells glasses, frames, and lenses.
- Offers sunglasses and contact lenses.
- Provides hearing aids and accessories.
- Operates a network of retail stores across Europe.
- Sells products through online stores.
- Invests in and operates optical and hearing aid businesses.
Business Model
- Vertically integrated model encompassing manufacturing, retail, and online sales.
- Focus on providing affordable and high-quality optical and hearing solutions.
- Extensive network of retail stores in key European markets.
Industry Context
The medical instruments and supplies industry is characterized by innovation, regulatory oversight, and evolving consumer preferences. The aging population and increasing awareness of eye and hearing health are driving demand for optical and hearing aid products. Fielmann AG competes with other major players in the European market, including those focused on low-cost solutions and those offering premium brands. The industry is also experiencing a shift towards online sales and telemedicine, requiring companies to adapt their business models.
Key Customers
- Individuals seeking vision correction.
- Individuals with hearing impairments.
- Fashion-conscious consumers looking for stylish eyewear.
- Customers seeking affordable optical and hearing solutions.
Financials
Chart & Info
Fielmann AG (FLMNY) stock price: Price data unavailable
Latest News
No recent news available for FLMNY.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FLMNY.
Price Targets
Wall Street price target analysis for FLMNY.
MoonshotScore
What does this score mean?
The MoonshotScore rates FLMNY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Marc Fielmann
CEO
Marc Fielmann has been the CEO of Fielmann AG since 2018. He represents the second generation of the Fielmann family to lead the company, following in the footsteps of his father, Günther Fielmann. Prior to becoming CEO, Marc Fielmann held various positions within the company, gaining experience in different areas of the business. He has a strong understanding of the optical and hearing aid market and is committed to driving innovation and growth.
Track Record: Since becoming CEO, Marc Fielmann has focused on expanding the company's online presence, investing in new technologies, and strengthening its brand. Under his leadership, Fielmann has continued to grow its market share in Europe and has expanded into new markets. He has also emphasized sustainability and social responsibility.
Fielmann AG ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. FLMNY is an ADR, meaning it allows U.S. investors to invest in Fielmann AG without the complexities of cross-border transactions. Each FLMNY ADR represents a certain number of Fielmann AG's shares traded on its home market.
- Home Market Ticker: FLMN trades on the Frankfurt Stock Exchange in Germany.
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: FLMN
FLMNY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure, may not meet minimum listing requirements, and carry higher risks compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks requires a higher degree of due diligence and risk tolerance.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or mismanagement
- Lack of regulatory oversight
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Research the company's management team and track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal proceedings against the company.
- Established presence in the European market
- Positive financial performance (based on available data)
- Experienced management team
- Strong brand recognition
- Membership in industry associations
FLMNY Healthcare Stock FAQ
What does Fielmann AG do?
Fielmann AG is a leading European optical and hearing aid provider. The company manufactures and sells a wide range of eyewear products, including glasses, frames, lenses, and sunglasses, as well as contact lenses and accessories. Additionally, Fielmann offers hearing aids and related accessories. The company operates through a network of retail stores across Europe and also sells its products through online channels. Fielmann's business model focuses on providing affordable and high-quality optical and hearing solutions to a broad customer base.
What do analysts say about FLMNY stock?
Analyst coverage of FLMNY may be limited due to its OTC listing and ADR status. However, based on available financial data, Fielmann AG demonstrates a solid financial profile with a gross margin of 80.2% and a profit margin of 7.5%. The company's P/E ratio of 19.57 suggests a reasonable valuation. Growth considerations include expansion into new markets, increased online sales, and product innovation. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.
What are the main risks for FLMNY?
The main risks for FLMNY include increased competition in the European optical and hearing aid market, fluctuations in currency exchange rates, and potential economic downturns affecting consumer spending. As an OTC-listed stock, FLMNY also carries risks associated with limited financial disclosure, low trading volume, and potential price volatility. Investors should carefully consider these risks before investing in FLMNY.
What are the key factors to evaluate for FLMNY?
Fielmann AG (FLMNY) currently holds an AI score of 48/100, indicating low score. Key strength: Strong brand recognition in Europe. Primary risk to monitor: Potential: Increased competition from existing players and new entrants.. This is not financial advice.
How frequently does FLMNY data refresh on this page?
FLMNY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven FLMNY's recent stock price performance?
Recent price movement in Fielmann AG (FLMNY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong brand recognition in Europe. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider FLMNY overvalued or undervalued right now?
Determining whether Fielmann AG (FLMNY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying FLMNY?
Before investing in Fielmann AG (FLMNY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market investments carry higher risks than exchange-listed stocks.